9 hasil untuk "Colin Reisner"

A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD

Edward M. Kerwin; Selwyn Spangenthal; Christine Kollar dkk.

Respiratory Research, Vol. 19 No. 1 · 2018 · Inggris · DOAJ Scopus

Abstract Background Long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) bronchodilators are key to the pharmacologic treatment of chronic obstructive pulmonary disease (COPD). This Phase IIb study investigated the safety and efficacy of four doses of the LAMA glycopyrronium…

Design of the MIST study: a double-blind, randomised, placebo-controlled phase 2b trial of pirfenidone solution for inhalation in patients with progressive pulmonary fibrosis

Tamera J Corte; Steven D Nathan; Felix Woodhead dkk.

BMJ Open Respiratory Research, Vol. 12 No. 1 · 2025 · Inggris · DOAJ Scopus

Introduction Progressive pulmonary fibrosis (PPF) is a debilitating progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). Oral pirfenidone has been studied in non-IPF ILDs, but in smaller academic studies, it did not…

Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study

Fernando J. Martínez; Klaus Friedrich Rabe; Gary T. Ferguson dkk.

American Journal of Respiratory and Critical Care Medicine · 2020 · Inggris · OpenAlex Scopus

Abstract Rationale In the phase III, 52-week ETHOS (Efficacy and Safety of Triple Therapy in Obstructive Lung Disease) trial in chronic obstructive pulmonary disease (COPD) (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) significantly reduced all-cause…

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

Klaus Friedrich Rabe; Fernando J. Martinez; Gary T. Ferguson dkk.

New England Journal of Medicine · 2020 · Inggris · OpenAlex Scopus

BACKGROUND: -agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been studied at single dose levels of inhaled glucocorticoid, but studies at two dose levels are lacking. METHODS: In a 52-week, phase 3, randomized trial to evaluate the efficacy and safety of triple therapy at two…

Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies

Fernando J. Martinez; Brian J. Lipworth; Klaus F. Rabe dkk.

Respiratory Research, Vol. 21 No. 1 · 2020 · Inggris · DOAJ Scopus

Abstract Background The Phase III PINNACLE studies assessed the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI), a dual long-acting bronchodilator for chronic obstructive pulmonary disease (COPD). Here we present a pre-specified pooled analysis of…

24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD

Colin Reisner; Gregory Gottschlich; Faisal Fakih dkk.

Respiratory Research, Vol. 18 No. 1 · 2017 · Inggris · DOAJ Scopus

Abstract Background Symptoms of chronic obstructive pulmonary disease may vary throughout the day and it is important that therapeutic approaches provide 24-h symptom control. We report the results of two phase IIIb crossover studies, PT003011 and PT003012, investigating the 24-h lung function…

Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD

Wilfried De Backer; Jan De Backer; Ilse Verlinden dkk.

Therapeutic Advances in Respiratory Disease, Vol. 14 · 2020 · Inggris · DOAJ Scopus

Background: Functional respiratory imaging (FRI) is a quantitative postprocessing imaging technique used to assess changes in the respiratory system. Using FRI, we characterized the effects of the long-acting muscarinic antagonist (LAMA), glycopyrrolate metered dose inhaler (GP MDI), and the…

Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

Colin Reisner; Leonardo M. Fabbri; Edward M. Kerwin dkk.

Respiratory Research, Vol. 18 No. 1 · 2017 · Inggris · DOAJ Scopus

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

Jean Chastre; Bruno François; Marc Bourgeois dkk.

Critical Care, Vol. 26 No. 1 · 2022 · Inggris · DOAJ Scopus

Abstract Background Ventilator-associated pneumonia caused by Pseudomonas aeruginosa (PA) in hospitalised patients is associated with high mortality. The effectiveness of the bivalent, bispecific mAb MEDI3902 (gremubamab) in preventing PA nosocomial pneumonia was assessed in PA-colonised…